[Oligoamnios associated with the use of magnesium dipyrone].
Oligohydramnios induced by indomethacin has been documented both clinically and experimentally. The same is not true for all the drugs inhibiting the synthesis of prostaglandins. The case of a full term pregnant woman diagnosed with renal cholic and treated with high doses of magnesium dipyrone who developed echographically diagnosed oligohydramnios at 60 h of initiation of the treatment is presented. Delivery was induced by the double intracervical application of 0.5 mg of prostaglandin E2 over an interval of 24 h. At 35 h of the discontinuation of magnesium dipyrone the patient was echographically reevaluated with the volume of the amniotic fluid being found to be normal. Although no reports have been found concerning oligohydramnios by magnesium dipyrone, the negative effect of this drug on urine flow in healthy individuals is known. In the absence of other hypotheses, the authors suggest that the use of high doses of this drug may significantly reduce fetal urine flow and be responsible for a drastic reduction in amniotic fluid. The adverse effect was determined as possible by evaluation of secondary effects by Naranjo's algorithm.
Catalán
J L
JL
Servicio de Farmacia, Hospital Dr. Peset, Valencia.
Santonja
J
J
Martínze
L
L
Jiménez
N V
NV
D003085:Colic / Q000188:drug therapy; D004177:Dipyrone / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy; D007751:Labor, Induced; D016104:Oligohydramnios / Q000139:chemically induced* / Q000000981:diagnostic imaging; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D011263:Pregnancy Trimester, Third; D012008:Recurrence; D016216:Ultrasonography, Prenatal
D004177:Dipyrone
Oligoamnios asociado al uso de dipirona magnésica.